Biocytogen Expands Global Footprint with the Opening of Biocytogen Europe Innovation Center in Germany
PR95195
BEIJING, March 28, 2022 /PRNewswire=KYODO JBN/ --
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (hereafter referred to as
"Biocytogen") announced the opening of the Biocytogen Europe Innovation Center
(BEIC) in Heidelberg, Germany.
Local government representatives, clinical experts, and colleagues and
collaborators from multi-national companies made speeches at the opening
ceremony. Dr. Vivian Tian, Head of BEIC, hosted the event, and introduced
Biocytogen's history, pipeline, and technology platforms, as well as the
strategic positioning of BEIC. The center's opening was also attended by local
and US pharmaceutical and biotechnology partners and colleagues, investigators
from research institutions, university hospitals, and other local biotechnology
professional organizations.
Germany has long been considered the "world's pharmacy" — home to Bayer, Merck
and Boehringer Ingelheim – with its strength most recently highlighted by the
success of the COVID-19 mRNA vaccine. In particular, Heidelberg is a scientific
hub in Germany with several renowned institutions, including the Germany Cancer
Research Center, the European Molecular Biology Laboratory, and four Max Planck
Institutes. This environment of innovation, world-class facilities and top
scientific talent positions the BEIC to form new collaborations with European
partners to develop and commercialize Biocytogen's clinical and preclinical
assets, as well as to further strengthen local partnerships to discover novel
antibody drugs emerging from Biocytogen's Project Integrum, a large-scale
initiative to develop antibodies with first-in-class and/or best-in-class
potential to over 1000 druggable targets.
"The opening of the Biocytogen Europe Innovation Center is a strategic and
momentous step forward in strengthening our global business, and it is a
welcome message to our peers here that we're looking forward to working
together with you to make innovative drugs that benefit patients around the
world," remarked Dr. Yuelei Shen, Chairman and CEO of Biocytogen.
About Biocytogen
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. is a global biotechnology
company that drives the research and development of novel antibody-based drugs.
Founded in 2009, the company is committed to becoming a global headstream of
new drugs to bring benefits to patients around the world. Using its proprietary
fully human antibody RenMabTM and RenLiteTM mice, Biocytogen has integrated its
monoclonal and bispecific antibody development platforms, in vivo drug efficacy
screening platforms and strong clinical development ability to streamline the
entire drug development process. Biocytogen is undertaking a large-scale
initiative to develop antibody drugs for more than 1000 potential druggable
targets, known as Project Integrum. With the implementation of Project
Integrum, Biocytogen has entered ongoing collaborations with dozens of partners
worldwide to produce first-in-class and/or best-in-class antibody drugs to
benefit patients. Currently, the company has established a pipeline of 12 core
products, with 2 products in phase II multi-regional clinical trials (MRCT) and
2 products in phase I trials. Headquartered in Beijing, Biocytogen has branches
in Haimen Jiangsu, Shanghai, Boston, USA and Heidelberg, Germany.
SOURCE: Biocytogen
Image Attachments Links:
Link: http://asianetnews.net/view-attachment?attach-id=417898
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。